Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 8/2017

01-08-2017 | Hypertension and the Heart (D Kitzman and B Upadhya, Section Editors)

Managing Hypertension in the Elderly: What is Different, What is the Same?

Author: Wilbert S. Aronow

Published in: Current Hypertension Reports | Issue 8/2017

Login to get access

Abstract

Purpose of Review

The goal is to discuss management of hypertension in the elderly.

Recent Findings

At 3.14-year follow-up of 2636 persons ≥75 years in the Systolic Blood Pressure Intervention Trial (SPRINT), compared with a systolic blood pressure (SBP) goal of <140 mmHg, a SBP goal of <120 mmHg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001). Absolute cardiovascular event rates were lower for the intensive treatment group within each frailty stratum. The incidence of serious adverse events was similar in both treatment groups.

Summary

The SPRINT trial provides very important information on the efficacy and safety of lowering the SBP to <120 mmHg in elderly adults with hypertension.
Literature
1.
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.CrossRefPubMedPubMedCentral
2.
Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J am Coll Cardiol. 2011;57:2037–114.CrossRefPubMed
3.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181.CrossRefPubMed
4.
Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.CrossRefPubMed
5.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortalty: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.CrossRefPubMed
6.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Jama. 1991;265:3255–64.CrossRef
7.
Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). Jama. 2000;284:465–71.CrossRefPubMed
8.
Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. Jama. 1997;278:212–6.CrossRefPubMed
9.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–64.CrossRefPubMed
10.
Liu L, Wang J-G, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823–9.CrossRefPubMed
11.
Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–72.CrossRefPubMed
12.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J med. 2008;358:1887–98.CrossRefPubMed
13.
Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol. 2014;176:219–26.CrossRefPubMedPubMedCentral
14.
Banach M, Zanchetti A, Bromfield S, Chlebus K, Howard G, Howard VJ, et al. What is targeted diastolic blood pressure in elderly patients-the results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study (abstract). Eur Heart J. 2014;35(suppl 1):abstract 4799.
15.
•• SPS3 Study Group, Benavente OR, Coffey CS, Conwitt R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;(382):507–15. Compared to a systolic blood pressure of 138 mm Hg, a systolic blood pressure of 127 mm Hg in 3020 patients with recent lacunar stroke nonsignificantly reduced at 3.7-year follow-up all stroke by 19%, disabling or fatal stroke by 19%, and myocardial infarction or vascular death by 16% and significantly reduced intracerebral hemorrhage by 63% (p = 0.03)
16.
17.
•• Wright JT, Jr WJD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J med. 2015;373:2103–16. Compared to a systolic blood pressure goal below 140 mm Hg, a systolic blood pressure goal below 120 mm Hg reduced in 9,361 persons at 3.26 years the primary composite outcome of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes by 25% (p < 0.0-01), all-cause mortality by 27% ( p = 0.003), heart failure by 38% ( p = 0.002), death from cardiovascular causes by 43% (p = 0.005) ), and. the primary composite outcome or death by 22% ( p < 0.001) CrossRefPubMed
18.
•• Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. A randomized clinical trial. Jama. 2016;315:2673–82. At 3.14-year median follow-up of 2,636 persons aged 75 years and older, mean age 79.9 years, compared with a systolic blood pressure goal of less than 140 mm Hg, a systolic blood pressure goal of less than 120 mm Hg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001) CrossRefPubMedPubMedCentral
19.
Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generizability of SPRINT results to the U.S. adult population. J am Coll Cardiol. 2016;67:463–72.CrossRefPubMed
20.
•• Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States. Projections from NHANES (National Health and Nutrition Examination Survey). Circulation. 2017;(135):1617–28. This study reported that intensive lowering of systolic blood pressure of all eligible United States adults could prevent 107,500 deaths per year and 46,100 cases of heart failure per year but cause an increase in serious adverse events
21.
Lonn EM, Bosch J, Jaramillo PL, Zhu J, Liu L, Pais P, et al. Blood pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J med. 2016;374:2009–20.CrossRefPubMed
22.
Whelton PK, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 blood pressure trial. JAMA Cardiol. 2016;1:855–6.CrossRefPubMed
23.
•• Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67. This meta-analysis demonstrated that every 10 mm Hg reduction in systolic blood pressure significantly reduced major cardiovascular events by 20%, coronary heart disease by 17%, stroke by 27%, and heart failure by 28%, which in the populations studied reduced all-cause mortality by 13% CrossRefPubMed
24.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefPubMed
25.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311:507–20.CrossRefPubMed
26.
Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb C. Evidence supporting a systolic blood pressure goal of less than 150 mm hg in patients aged 60 years or older: the minority view. Ann Intern med. 2014;160:499–503.CrossRefPubMed
27.
Krakoff LR, Gillespie RL, Ferdinand KC, Fergus IV, Akinboboye O, Williams KA, et al. 2014 hypertension recommendations from the Eighth Joint National Committee Members raise concerns for elderly black and female populations. J am Coll Cardiol. 2014;64:394–402.CrossRefPubMedPubMedCentral
28.
Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–42.CrossRefPubMed
29.
•• Weber MA, Schiffrin EL White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community. A Statement by the American Society of Hypertension and the International Society of Hypertension. 2014; 16: 14–26. These guidelines recommend that the blood pressure should be lowered to less than 140/90 mm Hg in adults aged 60 to 79 years and to less than 150'90 mm Hg in adults aged 80 years and older .
30.
•• Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J am Coll Cardiol. 2015;65:1998–2038. These guidelines recommend that the blood pressure should be reduced to less than 140/90 mm Hg in patients with coronary artery disease and with an acute coronary syndrome if they are aged 80 years and younger but to less than 150/90 mm Hg if they are older than 80 years of age CrossRefPubMed
31.
•• Padwal R, Rabi DM, Schiffrin EL. Recommendations for intensive blood pressure lowering in high-risk patients, the Canadian viewpoint. Hypertension. 2016;68:3–5. These Canadian guidelines recommend that high-risk adults aged 50 years and older with a systolic blood pressure of 130 mm Hg or higher obtained by an automated office blood pressure measurement should have a target systolic blood pressure goal of 120 mm Hg or lower CrossRefPubMed
32.
•• Gabb GM, Mangoni A, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guidelines for the diagnosis and management of hypertension in adults—2016. Med J Australia. 2016;205:85–9. These Australian guidelines state that selected high cardiovascular risk persons should have a systolic blood pressure goal of less than 120 mm Hg to improve cardiovascular outcomes CrossRefPubMed
33.
•• Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al., for the Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American academy of Family Physicians. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern med. 2017;166:430–7. Adults aged 60 years and older with a systolic blood pressure of 150 mm Hg and higher should have their systolic blood pressure reduced to less than 150 mm Hg. Adults aged 60 years and older with a history of stroke or transient ischemic attack should have their systolic blood pressure reduced to less than 140 mm Hg. Adults aged 60 years and older at high cardiovascular risk should have their systolic blood pressure reduced to less than 140 mm Hg
34.
35.
American Diabetes Association. Position statement. Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013;36(supplement 1):S11–S-66.CrossRef
36.
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 3. Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Supplements. 2012;2:357–62.CrossRef
37.
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 4. Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Supplements. 2012;2:363–9.CrossRef
38.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. Jama. 2003;289:2560–72.CrossRefPubMed
39.
Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacotherap. 2010;11:2599–607.CrossRef
40.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guidelines for the management of heart failure: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American College of Chest Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation. J am Coll Cardiol. 2013;62:1495–539.CrossRef
41.
Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362:591–2.CrossRefPubMed
42.
Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–9.CrossRef
43.
Erikkson S, Olofsson BO, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc dis. 1995;5:21–5.CrossRef
44.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS39. Br med J. 1998;317:713–20.CrossRef
45.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.CrossRefPubMed
46.
Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561–72.CrossRefPubMed
47.
Oparil S, Lewis CE. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm target? A protagonist view from the SPRINT trial (Systolic Blood Pressure Intervention trial). Circulation. 2016;134:1208–310.CrossRef
48.
Supiano MA, Williamson JD. Applying the Systolic Blood Pressure Intervention Trial results to older adults. Jags. 2017;65:15–21.CrossRef
49.
ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes. N Engl J med. 2010;362:1575–85.CrossRef
50.
Jones DW, Weatherly L, Hall JE. SPRINT. What remains unanswered and where do we go from here? Hypertension. 2016;67:261–2.PubMed
51.
Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WS, et al. Outcomes of combined cardiovascular risk factor management strategies in type 3 diabetes: The ACCORD randomized trial. Diabetes Care. 2014;37:1721–8.CrossRefPubMedPubMedCentral
52.
Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC Jr, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66:1123–9.
53.
Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure trial. Prevalence, incidence, and prognostic significance. Hypertension. 2016;68:888–95.CrossRefPubMed
54.
Aronow WS. Orthostatic hypotension in diabetics in the ACCORD (Action to control cardiovascular risk in diabetes) blood pressure trial. Hypertension. 2016;68:851–2.CrossRefPubMed
55.
Schiffrin EL, Calhoun DA, Flack JM. Do we need a new definition of hypertension after SPRINT? Am J Hypertens. 2016;29:1127–8.CrossRefPubMed
56.
Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J am Coll Cardiol. 2017;69:2446–56.CrossRefPubMed
Metadata
Title
Managing Hypertension in the Elderly: What is Different, What is the Same?
Author
Wilbert S. Aronow
Publication date
01-08-2017
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 8/2017
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-017-0764-8

Other articles of this Issue 8/2017

Current Hypertension Reports 8/2017 Go to the issue

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

The Elusive Search for Optimal Blood Pressure Targets

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Pathophysiology and Current Clinical Management of Preeclampsia

Letter to the Editor

Response to the Letter from Landman et al:

Therapeutic Trials (M Weir, Section Editor)

Role of Collecting Duct Renin in the Pathogenesis of Hypertension

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Endoplasmic Reticulum Stress, a Driver or an Innocent Bystander in Endothelial Dysfunction Associated with Hypertension?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits